Logo Image
Viewing
Opinion|Videos|January 2, 2025

Overview of Port Delivery System With Ranibizumab

Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating noninferior vision outcomes compared with monthly ranibizumab injections while reducing treatment burden through 6-month refill intervals.

Episodes in this series

Video content above is prompted by the following:

  • Can you provide an overview of the PDS with ranibizumab approved for treating neovascular age-related macular degeneration?
  • How does the device function?
  • Could you discuss the key outcomes from the Archway trial for PDS?

Related Content

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity
Video

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

View more
Treatment Optimization in the Evolving Anti-VEGF Era
Video

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

View more
Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida
Video

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

View more